Shares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results. The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with […]
Anika Therapeutics Inc.
RTI Surgical names new CEO, parts ways with CSO Hartill | Personnel Moves | January 31, 2017
RTI Surgical (NSDQ:RTIX) named Camille Farhat as its chief executive officer, effective March 15, 2017. Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he helped facilitate Boston Scientific (NYSE:BSX)’s $1.65 billion acquisition of the men’s and prostate health businesses. He has also held leadership positions with Baxter (NYSE:BAX), Medtronic (NYSE:MDT) and General Electric (NYSE:GE). “Today […]
Anika Therapeutics wins CE Mark for tennis elbow injection
Anika Therapeutics (NSDQ:ANIK) said today that it won CE Mark approval in the European Union for its Orthovisc-T injection. The Bedford, Mass.-based company’s treatment is indicated to relieve pain and restore function in tendons affected by tennis elbow, or chronic lateral epicondylosis. The sodium hyaluronate injection promotes tendon gliding and repair at the site of the […]
Anika’s pipeline & clinical data create steady growth in Q3
Shares in Anika Therapeutics (NSDQ:ANIK) rose yesterday after the company met expectations on Wall Street with its 3rd-quarter results. The Bedford, Mass.-based company posted profits of $8.9 million, or 59¢ per share, on sales of $25.8 million for the 3 months ended Sept. 30, for bottom-line growth of 6.8% on sales growth of 8.9% compared with the same period […]
Autonomic Technologies taps ex-Thoratec’s Pellegrini for CEO | Personnel Moves April 15, 2016
Anika Therapeutics wins CE Mark for Cingal knee treatment
Anika Therapeutics said today it won CE Mark approval in the European Union for its Cingal drug-combo designed to treat osteoarthritis-related knee pain. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the Bedford, Mass.-based company said. “The European approval of Cingal marks an […]
Anika assigned to FDA’s drug eval arm for Cingal approval
Anika Therapeutics today said the FDA’s Office of Combination Products assigned the company’s Cingal drug-combo to its Center for Drug Evaluation and Research arm to pursue premarket regulatory approval. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the company said. “While we […]
EnteroMedics names ex-Lanx chief Gladney as CEO | Personnel Moves
EnteroMedics (NSDQ:ETRM) said it named Dan Gladney, the former chief executive who led Lanx to an acquisition by Biomet, to be its new CEO effective Nov. 16. St. Paul, Minn.-based EnteroMedics said chairman, president & CEO Mark Knudson will become executive chairman when Gladney takes over the corner office until Jan. 1, 2016, when he will […]
DePuy sponsor’s Anika’s IDE bid for Monovisc hip treatment
Anika Therapeutics (NSDQ:ANIK) said today that DePuy Orthopedics will support its submission of an investigational device exemption to conduct a trial to expand the indication of Monovisc for the treatment of pain caused by osteoarthritis of the hip. Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopedics are the exclusive distributors of the Monovisc in the U.S., […]
Stryker taps new medical chief
Stryker (NYSE:SYK) tapped Dr. Scott Bruder, a Becton Dickinson & Co. (NYSE:BDX) veteran, to fill its newly created chief medical & scientific officer position.
Allergan profits slimmer despite plumper sales | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days: